Targeted Methylation of Two Tumor Suppressor Genes Is Sufficient to Transform Mesenchymal Stem Cells into Cancer Stem/Initiating Cells

I-Wen Teng, Pei-Chi Hou, Kuan-Der Lee, Pei-Yi Chu, Kun-Tu Yeh, Victor X. Jin, Min-Jen Tseng, Shaw-Jenq Tsai, Yu-Sun Chang, Chi-Sheng Wu, H. Sunny Sun, Kuen-daw Tsai, Long-Bin Jeng, Kenneth P. Nephew, Tim H.-M. Huang, Shu-Huei Hsiao, and Yu-Wei Leu

Abstract

Although DNA hypermethylation within promoter CpG islands is highly correlated with tumorigenesis, it has not been established whether DNA hypermethylation within a specific tumor suppressor gene (TSG) is sufficient to fully transform a somatic stem cell. In this study, we addressed this question using a novel targeted DNA methylation technique to methylate the promoters of HIC1 and RassF1A, two well-established TSGs, along with a two-component reporter system to visualize successful targeting of human bone marrow–derived mesenchymal stem cells (MSC) as a model cell system. MSCs harboring targeted promoter methylations of HIC1/RassF1A displayed several features of cancer stem/initiating cells including loss of anchorage dependence, increased colony formation capability, drug resistance, and pluripotency. Notably, inoculation of immunodeficient mice with low numbers of targeted MSC resulted in tumor formation, and subsequent serial xenotransplantation and immunohistochemistry confirmed the presence of stem cell markers and MSC lineage in tumor xenografts. Consistent with the expected mechanism of TSG hypermethylation, treatment of the targeted MSC with a DNA methyltransferase inhibitor reversed their tumorigenic phenotype. To our knowledge, this is the first direct demonstration that aberrant TSG hypermethylation is sufficient to transform a somatic stem cell into a fully malignant cell with cancer stem/initiating properties. Cancer Res; 71(13); 4653–63. ©2011 AACR.

Introduction

DNA methylation, a tightly regulated process during normal development, frequently becomes dysregulated during disease development including cancer (1–3). Although methylation-induced tumorigenesis has yet to be recapitulated experimen-
To monitor progression of TDM and cellular transformation, we also developed a 2-component system (11, 12). The first component consisted of regulation of tetracycline repressor (Tet) expression by the cloned target promoter sequence. A CMV promoter driving expression of a reporter (enhanced green fluorescence protein or EGFP) comprised the second component. A Tet repressor binding site, Tet operator, placed between the CMV and the EGFP, regulated EGFP expression. In the absence of DNA methylation, Tet expression was observed, and the expression of EGFP was silenced. Induction of DNA methylation silenced the Tet repressor and activated EGFP expression, allowing us to observe progression of DNA methylation in a living cell. Furthermore, if target loci DNA methylation was sufficient to induce cellular transformation, an EGFP-expressing cell behaved like a tumor (11, 12). It was of interest to use this system to initiate TDM in a somatic stem cell and monitor the subsequent effects on cellular transformation. Although spontaneous transformation of human mesenchymal stem cells (MSC) in vitro was recently described (13, 14), genetic disruptions of the p53 pathway, but not retinoblastoma (Rb), was sufficient to transform a fat-derived MSC (15), supporting the possibility that sarcoma could be initiated from MSC.

In the current study (work flow is illustrated in Supplementary Fig. S1A), we aimed to test the hypothesis that targeted DNA methylation is sufficient for cellular transformation, the promoter regions of HIC1C (hypermethylated in cancer 1) and RassF1A (ras-associated family protein isoforms 1A), 2 TSGs reported to be frequently silenced by DNA methylation in cancer (16–18), were cloned, methylated in vitro, and then transfected into the MSCs, individually or concurrently. HIC1C and RassF1A are involved in highly diverse, interacting cellular networks (16, 19, 20), and their loss of function could result in the recently described phenomenon of oncogenic addiction through p53 pathway (5). We thus hypothesized that hypermethylation of HIC1C and RassF1A would not only to directly suppress their tumor suppressor function but also disrupt multiple cellular networks resulting in tumorigenesis and cancer progression.

Materials and Methods

MSC isolation and characterization

Human MSC isolation and culture were carried out as described by Lee and colleagues (21). MSC expansion medium, passages, and culture condition were as described by Hsiao and colleagues (11).

In vitro DNA methylation

Four micrograms of PCR-amplified HIC1C and RassF1A promoters were incubated with 20 units of CpG methyltransferase (New England BioLabs) at 37°C for 4 hours in the presence of 160 μmol/L S-adenosylmethionine to induce methylation.

Validation of in vitro DNA methylation

Methylated DNA showing resistance to methylation-sensitive restriction enzymes (BstUI and HpaII) indicated complete conversion (Supplementary Fig. S2).

Cy5 labelling of the HIC1 promoter fragment

HIC1C DNA was labeled with LabelIT tracker Reagents (Mirus) according to the manufacturer’s instruction.

Transfection

The methylated PCR products (0.4 μg) were denatured at 95°C and then transfected into 5 × 10^6 cells using DMRIE-C (Invitrogen), according to the manufacturer’s instructions. Unmethylated PCR products were transfected as control. Cells were transfected three times at days 1, 3, and 5.

Semiquantitative real-time methylation-specific PCR

The semiquantitative methylation-specific PCR (qMSP) experiment was conducted and products were quantified according to the protocol described in Yan and colleagues (22). Briefly, bisulfite-converted genomic DNAs (0.5 μg) were subject to real-time PCR (RT-PCR) with methylation-specific primers (Supplementary Table S2). The qMSP reactions were carried out using the SYBR Green I PCR Kit (Toyobo) in an iQ5 Real-Time PCR instrument (Bio-Rad). Melting analysis was conducted followed by all of the PCR reactions to ensure a specific amplicon was generated. Col2A1 was used for standard curve construction and as loading control. Serial dilution of Col2A1 amplified bisulfite-converted DNA was used to generate standard curve. Methylation percentage was calculated as follows: (means of target gene)/(means of Col2A1); fold change was calculated as follows: (TDM methylation percentage)/(mock methylation percentage). Endogenous and exogenous HIC1C promoters were discerned by the reverse primers indicated in Supplementary Figures S1B and S3A.

Differential methylation hybridization

All procedures for the differential methylation hybridization (DMH) microarray were conducted as described in Leu and colleagues (18) using a human CpG island microarray (Agilent). Briefly, me_HErR-treated and control MSC genomic DNAs were digested into small fragments and then ligated with designed adaptors. Methylation-sensitive restriction enzymes (BstUI and HpaII) were used to discriminate the methylated and the unmethylated DNA fragments. Differences in methylation status were then amplified by PCR using the adaptor as primer. The amplicons from control and me_HErR-transfected cells were labeled with Cy3 and Cy5, respectively and then cohybridized onto the CpG microarray. After measuring the Cy3 and Cy5 intensity, the M value [M = log2 (Cy5 intensity/Cy3 intensity)] was used to indicate the difference in DNA methylation between 2 sources, and the L value [L = 0.5 × log2 (Cy5 × Cy3)] was used to indicate the intensity of individual loci. Both values were adjusted and normalized by LOWESS. A cutoff value of 4 based on the M value was used to identify the target loci.

Immunostaining

Cells were fixed in 2% formaldehyde/PBS, then permeabilized with 0.5% NP40/PBS. After blocked with horse serum/PBS (1:100), the slides were incubated with primary antibody in 3% bovine serum albumin (BSA)/PBS followed by 3 times of PBS washes. The cells were incubated with secondary
antibodies conjugated with Fluorescein or Texas Red (Vector Lab) in 3% BSA/PBS. After several PBS washes, the slides were mounted in mounting medium with 4',6-diamidino-2-phenylindole (DAPI; Vector Lab). The primary antibodies used were as follows: anti-HIC1 (Millipore), anti-RassF1A (Bioscience), anti-CD133 (Abcam), anti-Oct4 (Cell Signaling), and anti-Neuronal nuclei (NeuN; Chemicon).

5-Aza-dc-2’-deoxycytidine treatment

Control and me_H&R transfected MSCs were treated with 20 μmol/L (Fig. 1) or 5 μmol/L (Supplementary Fig. S6D) of 5-aza-dc-2’-deoxycytidine (5-aza-dc) or an equal final volume of dimethyl sulfoxide (DMSO) for 5 consecutive days.

Cloning of the human HIC1 and RassF1A promoters

Primer sequences for human HIC1 and RassF1A promoters are listed in Supplementary Table S1. Genomic DNA purified from human MSCs served as a template for PCR. Purified PCR products were ligated into the pyT&A cloning vector (Yeastern Biotech) according to the manufacturer’s protocol. Inserts were confirmed by restriction digests and sequencing. Cloning and TDM for the Salvador–Warts–Hippo (SWH) signaling pathway components were conducted using the same protocols and the primers were listed in Supplementary Table S1.

Semiquantitative RT-PCR

Total RNA isolation, first-strand cDNA synthesis, and detection of the transcripts were carried out as described (18). Briefly, total RNA (2 μg) was reverse transcribed using the SuperScript III reverse transcriptase (Invitrogen). The semiquantitative RT-PCR (qRT-PCR) was then carried out by SYBR Green I PCR Kit (Toyobo) in an iQ5 Real-Time PCR instrument (Bio-Rad). A serial dilution of glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-amplified cDNA was used as control to generate standard curve and GAPDH from each samples was used as loading control. The primers are listed in Supplementary Table S2.

Cell survival assay

In 96-well plates, 20 μL of MTT solution (Sigma-Aldrich; 5 mg/mL) was added to each well containing different number of cells and incubated at 37°C for 5 hours. The reaction was
terminated by adding 200 μL of DMSO, and absorbance was measured at 595 nm.

**Soft agar assay**

Cells were plated at a density of $5 \times 10^4$ per well in soft agar. After 2 weeks of culture, cells were stained with 0.01% crystal violet, and the number of spheres (>50 cells) from each dish was counted.

**Transwell study**

Cells were plated at a density of $5 \times 10^4$ per well into the hanging cell culture insert (Millipore), and the redistribution of the cells on the other side of the insert was observed, stained, and quantified.

**In vivo tumorigenesis and serial transplantation of xenografts**

Six-week-old nude mice (Narl: ICR-Foxn1nu) were inoculated subcutaneously with $1 \times 10^4$ me_HIC1-transfected or control MSCs. Growth of tumours was monitored until they reached 0.8 cm in diameter. Then, tumors were surgically removed and subcultured in MSC medium on low attachment plates until spheres were observed again. The same number of subcultured cells was inoculated into a new nude mouse, and the entire procedure ($n = 9$) was repeated 4 more times ($n = 36$ in total).

**Immunohistochemistry**

Tumor masses surgically removed from nude mice inoculated with me_HIC1-transfected MSCs were paraffin embedded and sectioned at 4 μm or embedded in optimum cutting temperature (OCT) and sectioned on a cryostat (Leica) at 12 μm. Sections were stained with the indicated antibodies, and detection was carried out with Vectastain (Vector Lab) for the paraffin sections and Fluorescein- or Texas red–conjugated anti-mouse or rabbit IgG (Vector Lab) for the cryosections, followed by DAPI staining. Sections were also stained with hematoxylin and eosin (H&E; Vector Lab) for pathologic exams.

**Lineage-specific induction of MSCs**

Transfected MSCs (mock or me_HIC1) were plated onto 6-well plates at $5 \times 10^4$ cells per well. After attachment, the medium was replaced with neuronal preinduction medium [Dulbecco’s modified Eagle’s media (DMEM) with 20% FBS, 10 ng/mL basic fibroblast growth factor (bFGF), and 1 mmol/L β-mercaptoethanol] for 24 hours, followed by neuronal induction medium [DMEM with 100 μmol/L butylated hydroxyanisole (BHA), 10 μmol/L forskolin, 2% DMSO, 25 mmol/L KCl, 2 mmol/L valproic acid, 1 x B27 supplement, 10 ng/mL bFGF, 10 ng/mL platelet-derived growth factor (PDGF)], Morphologic changes and NeuN expression were used to validate neuronal induction. Osteocyte induction medium consisted of DMEM, 10% FBS, 10 mg/mL penicillin/streptomycin, 100 mmol/L dexamethasone, 10 mmol/L β-glycerophosphate, and 50 μmol/L l-ascorbic acid-2-phosphate. Cells were treated with the osteocyte induction medium for 10 days and then subject to alkaline phosphatase (Sigma-Aldrich) staining.

**Construction of two-component reporter system**

The construction of HIC1 2-component reporter system is described and illustrated in Supplementary Figure S4. Both constructs were sequence validated and used to transfect the MSCs and transfected cells were selected with hygromycin and G418 resistance. PCR were carried out to validate the integrations of both constructs (HIC1-TR and EG1; Supplementary Fig. S4B). MSC clones carrying both reporter constructs were treated with doxycycline (Supplementary Fig. S4B). Doxycycline-induced EGFP expression indicates the reporter system is functional.

**Human subjects**

Isolation and characterization of human MSCs were conducted under Institutional Review Board (IRB) regulations of the Chang Gung Memorial Hospital.

**Animals**

The use of mice followed the regulations and protocols reviewed and approved by the Institutional Animal Care and Use Committee at the National Chung Cheng University.

**Results**

**Targeted HIC1 and RassF1A methylation transforms MSCs**

In vitro methylated (validation of in vitro methylation is shown in Supplementary Fig. S2) or unmethylated (control) HIC1 and RassF1A promoter DNA fragments were transfected into human bone marrow–derived MSCs mixed population (MSC_MP) alone or in combination. Transfection of methylated HIC1 (me_HIC1) or methylated RassF1A (me_RassF1A) increased endogenous HIC1 or RassF1A promoter methylation, as detected by qMSP (Fig. 1A, top). MSP amplification was confirmed by sequencing in Supplementary Fig. S3A and B) and the expression of endogenous HIC1 or RassF1A decreased accordingly, as detected by immunostaining (Fig. 1A, bottom). TDM was confirmed by bisulfite sequencing (Supplementary Fig. S3C and D).

Loss of contact inhibition was used as a screening criterion for MSC transformation (Fig. 1B, left). Transfection and selection of transformed MSCs are illustrated in Supplementary Figure S6A. Cotransfection of methylated HIC1 and RassF1A (me_HIC1 and me_RassF1A) caused formation of anchorage-independent aggregates, similar to the transformed phenotype in attached cultures, whereas the controls and cells transfected with either me_HIC1 or me_RassF1A alone remained contact inhibited (Fig. 1B, left middle two). When cultured in low attachment dishes, both methylated- and mock-transfected MSCs formed spherical aggregates (Fig. 1B, right), suggesting that these me_HIC1-transfected MSCs retained their self-renewal property.

To confirm that loss of anchorage dependence was due to DNA hypermethylation, cells were treated with the DNMT inhibitor 5-aza-dc, 5-Aza-dc treatment decreased the hypermethylation level of endogenous HIC1 and RassF1A in the me_HIC1-transfected MSCs (Fig. 1C and Supplementary Fig. S6D) and abrogated the formation of me_HIC1-induced
aggregates (Fig. 1D, right and Supplementary Fig. S6D, top). These data indicate that DNA hypermethylation of both HIC1 and RassF1A potentially transformed somatic MSCs and rendered them anchorage independent. Moreover, the requirement for methylation of both HIC1 and RassF1A for MSC transformation supports the notion that cancer initiation and development is a multistep process.

Figure 2. Visualization of targeted DNA methylation and MSC transformation. A, schematic diagram of the reporter system (left; construction and validation of the obtained clones in Supplementary Fig. S4). Targeted HIC1 methylation was visualized by EGFP fluorescence (right middle) including RassF1A TDM led to EGFP-expressing cell aggregation (right). B, tracking TDM. Unmethylated (control) and/or methylated HIC1 and RassF1A DNA fragments were transfected into the MSCs harboring both constructs shown in A. me_HIC1 was labeled with Cy5 to track the distribution of transfected DNA in the MSCs, after induction of EGFP expression. Only the Cy5-containing cells expressed EGFP, confirming the specificity of the targeted methylation. C, detecting the methylation state of the exogenous HIC1 promoter (HIC1-TR) and the expression of EGFP. qMSP was carried out to quantify exogenous HIC1 promoter region methylation using HIC1-specific and vector-specific primers (left). Increased HIC1-TR methylation was observed only in the me_HIC1-targeted MSCs. EGFP expression increased accordingly, as detected by qRT-PCR (right). D, validation of HIC1 and/or RassF1A TDM. MSCs were treated with methylated HIC1 and/or RassF1A as C. qMSP was used to detect methylation changes at endogenous HIC1 or RassF1A promoter (left). qRT-PCR was used to determine changes in expression of endogenous HIC1 or RassF1A (right).
Validation of TDM by two-component reporter system

To confirm that the TDM caused silencing at the transcriptional level and induced aggregates within the targeted cells, we used a 2-component reporter system (11, 12) to mark and track methylation-mediated silencing of the HIC1 promoter in live cells (single colonies, SC). In this system, the HIC1 promoter regulates expression of the EGFP reporter construct (Fig. 2A flow diagram on left; reporter system construction is illustrated in Supplementary Fig. S4). Methylation of the HIC1 promoter alone did not result in phenotypic changes but caused HIC1 promoter silencing, as indicated by increased EGFP expression (Fig. 2A, right middle). However, concomitant methylation of RassF1A and HIC1 led to cell aggregates containing EGFP-expressing (i.e., HIC1 silenced) cells (Fig. 2A, right and Supplementary Fig. S6B and C).

To track the distribution of transfected DNAs, me_HIC1 construct was labeled with Cy5 prior to transfection. Cy5 transfected cells were labeled with Cy3, me_H&R-transfected cells were labeled with Cy5. Red and green lines correspond to hyper- and hypomethylation, respectively. Right, arrows highlight hypermethylated genes in selected array blocks. B, validation of altered methylation by qMSP. C, visualization of affected loci by unsupervised pathway finding (PathVisio; ref. 44). D, stemness of me_H&R-transfected MSCs. Immunostaining for Oct4 and CD133 stem cell markers (top left). Phase contrast and immunostaining of MSCs during neuronal induction (right) and osteocyte induction (bottom left). pre-NIM, neuronal preinduction medium; NIM, neuronal induction medium. The neuronal differentiation was indicated by NeuN immunostaining. AP, alkaline phosphatase.

The MSC nuclei. EGFP was detected in these Cy5-containing/ transfected MSC (Fig. 2B, columns 3, 7, 8). When me_HIC1 was used to transfect the cells, qMSP analysis further showed increased methylation of exogenous HIC1 promoter (HIC1-TR; Fig. 2C, left), and EGFP expression increased accordingly (Fig. 2C, right). The me_RassF1A, RassF1A, or control (unmethylated) HIC1 DNAs failed to induce the EGFP expression, further indicating that we successfully and specifically methylated the HIC1 promoter. Targeted HIC1 methylation had no effect on the methylation state of the endogenous RassF1A promoter and vice versa (Fig. 2D), consistent with our previous report that the TDM is locus-specific (11, 12). Combined transfection of me_HIC1 and me_RassF1A resulted in methylation of both endogenous loci, as determined by qMSP (Fig. 2D, left), as well as concomitant silencing of both genes (qRT-PCR; Fig. 2D, right). Data from the 2-component reporter system further confirmed that our targeting method caused gene silencing at the transcriptional level and that aberrant DNA methylation of both HIC1 and RassF1A might transform...
normal somatic stem cells. Furthermore, our data indicated that methylation of HIC1 initiated the accumulation of epigenetic changes in MSCs and increased the potential for transformation. In normal cells, the transformation process can be prohibited by gatekeepers or roadblocks, such as RassF1A; thus, gatekeeper silencing can allow for excess cell proliferation and/or genome corruption, increasing the probability of neoplastic transformation.

**Transfection of me_H&R induces genome-wide DNA methylation changes in MSC**

To further investigate changes in DNA methylation following me_H&R targeting, genome-wide methylation profiling of me_H&R-transfected and control MSCs was carried out using DMH microarrays (23). As shown in the methylation heatmap, transfection of me_H&R induced extensive disruption in the MSC epigenome (Fig. 3A, left) Individual loci (Fig. 3A, right) displaying hypermethylation (SOX7, ADAM9, and GATA6) or hypomethylation (CXXC1, OSBP, and TBX2) were validated by qMSP (Fig. 3B). On the basis of the wide range of cellular functions associated with HIC1 and RassF1A (16, 19, 24), it was not surprising to observe global changes in the MSC methylome. Furthermore, as both HIC1 and RassF1A were reported to function as TSGs that act via p53, we conducted unsupervised ontological analysis of the array target loci and found that p53 and its associated signaling components were significantly altered by me_H&R transfection (Fig. 3C and Supplementary Fig. S7, target loci with the p53 binding domain are listed in Supplementary Table S3). Our finding that MSC transformation is strongly associated with altered p53 function is consistent with a previous report using genetic approaches (15).

**Characteristics of me_H&R-transformed MSCs**

To determine whether the me_H&R-transformed MSCs retained stemness, me_H&R transfected MSCs were labeled with antibodies against stem cell surface markers CD133 and Oct4 and induced to differentiate. Expression levels of CD133 and Oct4 were unaffected by me_H&R transfection (Fig. 3D, top left). Multipotency was assayed by neuronal induction and...
osteogenic differentiation. MSCs transfected with me_H&R were able to differentiate into neuron-like cells (Fig. 3D, right, indicated by NeuN staining) and osteoblasts (Fig. 3D, left bottom, alkaline phosphatase positive). These data indicate that although concurrent methylation of HIC1 and RasG1A TSGs was sufficient to transform MSCs, as indicated by altered anchorage dependence and methylation patterns, the transformed MSCs retained somatic stem cell characteristics.

The proliferation and invasion capability of transformed MSCs were evaluated by using colony formation and Transwell studies. Colony formation was substantially increased (~8-fold, n = 6) in me_H&R-transfected cells versus controls (Fig. 4A and Supplementary Figs. S8A and S9A), and this was inhibited by 5-aza-dc treatment (Fig. 4A and Supplementary Fig. S8A). In Transwell studies, MSCs transfected with me_H&R exhibited greater migratory capability (Fig. 4B and

![Figure 5](image_url)

**Figure 5.** Immunohistochemistry of xenografts from me_H&R-transfected MSCs. A, stem cell marker expression in xenografts. Representative images of cells positive for CD44, CD133, or Oct4 from the serial sections of xenograft tumors. B, representative images from xenografts (n = 36) containing heterogeneous cell types of either epithelial or mesenchymal lineage (vimentin). C, expression of lineage-specific markers (left: NSE; right: LCA) was observed in many CD133-positive cells, or lineage-specific marker expressing cells surrounded CD133-positive cells. D, top, images of coexpression of CD133 and vimentin in a subpopulation of control MSCs (top), me_H&R-transfected MSCs (middle), and subcultures derived from me_H&R-transfected MSC xenografts (bottom). Bottom, simplified model for mechanisms by which normal somatic stem cells (primary) can gradually become tissue-specific tumor cells, via transformation and clonal selection occurring at niches in primary or secondary sites. Colored circles represent different lineages. EMT: epithelial-to-mesenchymal transition; GI, gastrointestinal.
Supplementary Figs. S8B and S9B). Taken together, these results indicated that MSCs with concurrent methylation of HIC1 and RassF1A acquired a cancer phenotype.

Acquired drug resistance is a hallmark of malignancy and a characteristic of a cancer stem cell (CSC) phenotype. Cisplatin treatment induced cell death in control MSCs in a dose-dependent manner, but the drug was much less effective in me_H&R-transfected MSCs, even at a very high dose (100 μmol/L; Fig. 4C), further indicating that concurrent HIC1 and RassF1A methylation transformed normal somatic stem cells into CSC-like.

To examine the tumorigenic capacity of the me_H&R-transfected MSCs in vivo, immunodeficient nude mice were inoculated with me_H&R-treated MSCs. As shown in Figure 4D, 100% of these mice developed tumors (n = 9), whereas the mice inoculated with control MSCs remained tumor free. Immunohistochemistry revealed the presence of CD133+ stem cells in the tumors (Fig. 4D, bottom left). Furthermore, the tumors were soft tissue sarcomas like (Figs. 4D, right and 5A and B), consistent with this type of malignancy in mice with heterozygous disruption of HIC1 (17).

**Expression of stem cell markers in me_H&R MSC-derived tumors**

We examined xenografts from serial transplantations for expression of known stem cell markers by immunohistochemistry. As shown in Figure 5A, expression of CD44, CD133, and Oct4 was observed, substantiating the CSC-like phenotype. Vimentin expression was also detected, confirming the mesenchymal origin of the xenografts. Clonal expression of a panel of epithelial markers, including neuron-specific enolase (NSE), S-100, cytokeratin, desmin, and leukocyte common antigen (LCA; Fig. 5B), further showed the ability of CSCs to differentiate into heterogeneous tumors. In addition, expression of both stem cell (CD133) and mesenchymal (vimentin) markers in sparsely scattered cells of me_H&R tumors showed that the xenografts were derived from inoculated me_H&R MSCs (Fig. 5C). Although we observed slight enrichment of CD133+/vimentin+ cells in serial transplantation experiments (Supplementary Fig. S10A), the overall percentage remained low, in agreement with previous observations (25) that CSCs continue to form a small proportion of the overall tumor even after in vitro enrichment and xenograft transplantation.
Transformation specificity induced by concurrent methylated of HIC1 and RassF1A

To establish that MSC transformation was due to concomitant methylation of HIC1 and RassF1A and not accumulation of targeted genes, we simultaneously methylated 9 genes in the SWH signaling pathway by TDM in MSCs (ref. 20; Fig. 6A). Abnormal SWH signaling pathway has been associated with tumorigenesis in both mammalian cells and Drosophila (26, 27), and RassF1A is a SWH pathway component controlling cellular proliferation, survival, antiapoptosis, organ size, and cell contact inhibition (20, 28). Because loss of function of these 9 genes (Fig. 6A) has been reported in various cancers (20), we hypothesized that methylation of these SWH signaling pathway genes (i.e., "me_SWH") could cause MSC transformation. me_SWH-treated MSCs displayed loss of contact inhibition (Fig. 6B), increased colony formation in soft agar assays (Supplementary Fig. S9A), and were invasive in Transwell assays (Supplementary Fig. S9B). Furthermore, me_SWH-treated MSCs retained stemness markers and could be induced to differentiate (Fig. 6C). However, these cells were not tumorigenic in nude mice assay (Fig. 6D). Taken together, these results support a unique role for the combination of methylated HIC1 and RassF1A in MSC transformation. Furthermore, increasing the number of methylated loci within the SWH pathway did not result in transformation of MSC, even though RassF1A was included in the me_SWH loci.

Collectively, our data showed that concurrent methylation of HIC1 and RassF1A was sufficient to transform MSCs. The observation that pluripotency was maintained suggests that these cells had acquired a CSC phenotype. Increased proliferation is often accompanied with increased genetic and/or epigenetic mutations (29), which further enhance transformation and clonal selection during mesenchymal-to-epithelial transition (MET; refs. 30–32). In more permissive environments, including nude mice, subpopulations of inoculated me_HIC1 produced NSE- and LCA-positive epithelial cells (Fig. 5C) or other cell types (Supplementary Fig. S10B). The acquired differentiation capacity, and perhaps later migratory capability, may allow these CSC-like cells to either remain in their original location or migrate to form secondary tumors (Fig. 5D, bottom scheme). Bioinformatic analysis further revealed the presence of p53 binding elements within the targets identified by DMH (Supplementary Table S3), suggesting a central role for p53 in MSC oncogenic transformation. The tumor suppressor activities of both HIC1 and RassF1A are due, in part, to p53 activation, in agreement with previous genetic findings (17). Concordant silencing of HIC1 and RassF1A by DNA methylation may impair p53-mediated apoptosis and contribute to the tumorigenic ability of MSCs.

Discussion

Here, we elucidated the role of DNA methylation in the transformation of somatic stem cells into CSC-like cells. Bone marrow–derived MSCs are known to play important roles in cancer progression and metastasis (33–35). By providing a microenvironment that enhances primary tumor growth, invasiveness, and metastasis, MSCs have the capacity to mobilize to other organs, providing a niche suitable for the disseminated cancer cells to metastasize to distant tissues (33). Our data show that in addition to these 2 supporting roles, MSCs may play a previously unidentified role in tumorigenesis, as abnormal DNA hypermethylation of HIC1 and RassF1A, 2 TSGs involved in functionally diverse, interacting networks, transformed MSCs from normal somatic stem cells to cancer-like stem cells.

Concordant methylation of HIC1 and RassF1A has been identified in advanced ovarian cancer (36), and HIC1 shows increased concurrent hypermethylation with other genes in advanced myelodysplasia syndrome (37), suggesting that disturbance of HIC1-associated networks may be essential for tumor initiation. Unlike RassF1A, which can be inactivated by either genetic or epigenetic mechanisms, repression of HIC1 is mainly caused by DNA methylation (16). Thus, DNA hypermethylation of HIC1 could predispose cells to cancer development (Fig. 2A). A second epigenetic hit, such as RassF1A methylation, may then permit more efficient cancer development. However, it is also possible that hypermethylation of RassF1A results in further epigenomic disturbances, rendering a cell more susceptible to cancer-causing insult(s). Our data further show that DNA methylation is a cause rather than a consequence of malignancy, and p53 may be at the center of this oncogenic transformation. p53-dependent apoptosis plays an integral part in tumor growth, progression, and drug resistance development (38), and the tumor suppressor ability of both HIC1 and RassF1A is due to p53 activation. Thus, concordant silencing of HIC1 and RassF1A by DNA methylation may synergistically disrupt the p53-mediated apoptotic pathway and contribute to the observed tumorigenic ability of MSCs.

The origin of CSCs or cancer-initiating cells has been widely debated. These cells may arise either from deregulated somatic stem cells or from dedifferentiated mature cells (4, 7, 8, 39–42). It has been reported that several hypermethylated genes, including HIC1 and RassF1A, in adult cancer are unmethylated in embryonic stem cells and only partially methylated in embryonic carcinomas (43). In this study, we show that forced epigenetic silencing of HIC1 and RassF1A is sufficient to confer normal somatic stem cells with malignant properties, including loss of contact inhibition, increased colony formation, migration capability, drug resistance, and tumor formation in inoculated mice. Moreover, the cells retained sensitivity to neuron- and osteocyte-induction and displayed both lineage-specific markers and stem cell markers in xenografts. Thus, we reason that methylation of both HIC1 and RassF1A triggers the transformation of normal somatic stem cells to CSC-like cells. As proposed in Figure 5D, this transition may promote additional transforming events and further cellular selection. We further propose that under the influence of different environmental niches, these transformed stem cells could give rise to tissue-specific cancers.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.
Grant Support

Y.-W. Leu (NRPGM, NSC-98-3112-B-194-001 and NSC-97-2320-B-194-003-MY3), S.-H. Hsiao (NSC-96-2320-B-194-004), and S.-J. Tsai and Y.-W. Leu (NSC-97-2667-B-006-003) are supported by the National Science Council, Taiwan. K.P. Nephew and T.H.-M. Huang are supported in part by NIH grants CA085289 and CA113001.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 17, 2010; revised March 27, 2011; accepted April 18, 2011; published OnlineFirst April 25, 2011.
Targeted Methylation of Two Tumor Suppressor Genes Is Sufficient to Transform Mesenchymal Stem Cells into Cancer Stem/Initiating Cells

I-Wen Teng, Pei-Chi Hou, Kuan-Der Lee, et al.

Cancer Res 2011;71:4653-4663. Published OnlineFirst April 25, 2011.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-10-3418

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2011/04/25/0008-5472.CAN-10-3418.DC1

Cited articles
This article cites 44 articles, 12 of which you can access for free at:
http://cancerres.aacrjournals.org/content/71/13/4653.full#ref-list-1

Citing articles
This article has been cited by 4 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/71/13/4653.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.